CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS

Rizaldy Taslim Pinzon; Rosa De Lima Renita Sanyasi

doi:10.24071/jpsc.00606

CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS

Rizaldy Taslim Pinzon^(1*), Rosa De Lima Renita Sanyasi⁽²⁾,

(1) Duta Wacana Christian University School of Medicine Yogyakarta Indonesia
(2) Internship Doctor at dr. Efram Harsana Air Force Hospital, Raya Solo Street, Maospati, Magetan, East Java, 63392
(*) Corresponding Author

Abstract

Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis (MS) by the Indonesian Food and Drug Administration. The number of MS patients is increasing in Indonesia. There is a critical need of systematically reviewing the new medication for both efficacy and safety. This review aimed to appraise the clinical evidences of oral fingolimod for the effective treatment of relapsing MS. We searched in Pubmed database. We limited our search to only articles that were in full text, published within the last 10 years, and in English. We used the Jadad scale to measure the quality of the evidences. We only found 3 trials, all conducted with randomized and double blind design. The three trials were: the FREEDOMS I, FREEDOMS II, and TRANSFORMS studies. The FREEDOMS studies compared with placebo, and the TRANSFORMS study compared with injectable interferon. All of the studies have good quality in methodology (Jadad scale >3). The results of the three studies showed the benefit of oral fingolimod in reducing MS relapse compared with placebo with relative risk reduction range from 48% to 54%, and also in reducing new lesions in T2 brain MRI with relative risk reduction range from 35% to 74%. Our critical appraisal found that oral fingolimod improved clinical outcomes. The availability of oral fingolimod in Indonesia makes it one of the options in treatment of MS relapse in Indonesia and has been demonstrated to be effective and safe with relatively small risk.

Keywords

critical appraisal; fingolimod; multiple sclerosis; relapse

Full Text:

PDF

References

Antezana, A., 2014. Symptomatic Management of Multiple Sclerosis. The Neurol Report., 7 (1), 39-46.

Archer, M., Oderda, G., 2013. Fingolimod (Gilenya) Drug Review. University of Utah, College of Pharmacy.

Ayzenberg, I., Hoepner, R., and Kleiter, I., 2016. Fingolimod for Multiple Sclerosis and Emerging Indications: Appropriate Patient Selection, Safety Precautions, and Special Considerations. Ther Clin Risk Manag., 12, 261-272.

Berger, V.W., Alperson S.Y., 2009. A General Framework for The Evaluation of Clinical Trial Quality. Rev Recent Clin Trials, 4 (2), 78-88.

Berkovich, R., 2013. Treatment of Acute Relapses in Multiple Sclerosis. Neurotherap., 10, 97-105.

Bomprezi, R., 2015. Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Overview. Ther Adv Neurol Disord., 8 (1), 20-30.

Chun, J., Hartung, H.P., 2010. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clin Neuropharmacol., 33 (2), 91-101.

David, O.J., Kovarik, J.M., Schmouder, R.L., 2012. Clinical Pharmacokinetics of Fingolimod. Clin Pharmacokinet., 51 (1), 15-28.

Esposito, F., Radelli, M., Martinelli, V., Sormani, M.P., Boneschi, F.M., Moiola, L., Rocca, M.A., Rodegher, M., Comi, G., 2010. Comparative Study of Mitoxantrone Efficacy Profile in Patients with Relapsing-Remitting and Secondary Progresive Multiple Sclerosis. Sage Journ., 16 (12), 1490-1499.

Fitzner, D., Simons, M., 2010. Chronic Progressive Multiple Sclerosis Pathogenesis of Neurodegeneration and Therapeutic Strategies. Current Neuropharmacol., 8, 305-315.

Fonseca, J., 2015. Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice.

Goldenberg, M.M., 2012. Multiple Sclerosis Review. P&T., 37 (3), 175-184.

Huismann, E., Papadimitropoulou, K., Jarrett, J., Bending, M., Firth, Z., Allen, F., Adlard, N., 2017. Systematic Literature Review and Network Meta-analysis in Highly Active Relapsing-Remitting Multiple Sclerosis and Rapidly Evolving Severe Multiple Sclerosis. BMJ Open, DOI: 10.1136/bmjopen-2016-013430.

Kalincik, T., Brown, J.W.L., Robertson, N., Willis, M., Scolding, N., Rice, C.M., Wilkins, A., Pearson, O., Ziemssen, T., Hutchinson, M., McGuigan, C., Jokubaitis, V., Spelman, T., Horakova, D., Hardova, D., Trojano. M., Izquierdo, G., Lugaresi, A., Prat, A., Giard, M., Duquette, P., Grammond, P., Alroughani, R., Pucci, E., Sola, P., Hupperts, R., Lechner-Scott, J., Terzi, M., Van Pesch, V., Rozca, C., GrandMaison, F., Boz, C., Granella, F., Slee, M., Spitaleri, D., Olascoaga, J., Bergamaschi, R., Verheul, F., Vucic, S., McCombe, P., Hodgkinson, S., Sanchez-Menoyo, J.L., Ampapa, R., Simo, M., Csepany, T., Ramo, C., Cristiano, E., Barnett, M., Butzkueven, H., Coles, A., 2017. Treatment Effectiveness of Alemtuzumab Compared with Natalizumab, Fingolimod and Interferon Beta in Relamsing-Remitting Multiple Sclerosis: A Cohort Study. Lancet Neurol., 16 (4), 271-281.

Kasper L.H., Reder, A.T., 2014. Immunomodulatory Activity of Interferon-Beta. Annals of Clin and Translational Neurol., 1 (8), 622-631.

Kieseier, B.C., Jeffery D.R., 2010. Chemotherapeutics in the Treatment of Multiple Sclerosis. Ther Adv Neurol Disord., 3 (5), 277-291.

Lalive, P.H., Neuhaus, O., Benkhoucha, M., Burger, D., Hohlfeld, R., Zamvil, S.S., Weber, M.S., 2011. Glatiramer Acetate in the Treatment of Multiple Sclerosis: Emerging Concepts Regarding Its Mechanism of Action. CNS Drugs., 25 (5), 401-414.

Leary, S.M., Parter B., Thompson, A.J., 2005. Multiple Sclerosis: Diagnosis and the Management of Acute Relapse. Postgrad Med J., 81, 302-308.

Loma, I., Heyman, R., 2011. Multiple Sclerosis: Pathogenesis and Treatment. Current Neuropharmacol., 9, 409-416.

Longbrake, E.E., Cross, A.H., Salter, A., 2016. Efficacy and Tolerability of Oral Versus Injectable Disease-Modifying Therapies for Multiple Sclerosis in Clinical Practice. Experiment Translation and Clin., 2, 1-10.

Lublin, F.D., Reingold, S.C., Cohen, J.A., Cutter, G.R., Srensen P.S., Thompson, A.J., Wolinsky, J.S., Balcer L.J., Banwell B., Barkhof, F., Bebo, B., Calabresi, P.A., Clanet M., Comi, G., Fox, R.J., Freedman, M.S., Goodman, A.D., Inglese, M., Kappos, L., Kieseier, B.C., Lincoln, J.A., Lubetzki, C., Miller, A.E., Montalban, X., OConnor, P.W., Petkau, J., Pozzili, C., Rudick, R.A., Sormani, M.P., Stve, O., Waubant, E., Polman, C.H., 2014. Defining the Clinical Course of Multiple Sclerosis. Neurol., 83, 278-286.

Marcus, J.F., Waubant, A.L., 2012. Updates on Clinically Isolated Syndrome and Diagnostic Criteria for Multiple Sclerosis. The Neurohospital. 3 (2), 65-80.

McKay, K.A., Kwan, V., Duggan, T., Tremlett, H., 2015. Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. BioMed Research Intern., DOI: 10.1155/2015/817238.

Mendes, A., S, M.J., 2011. Classical Immunomodulatory Therapy in Multiple Sclerosis: How It Acts, How It Works. Arg Neurosiquiatr., 69 (3), 536-543.

Minagar, A., 2013. Current and Future Therapies for Multiple Sclerosis. Scientifica. DOI: 10.1155/2013/249101.

Nicholas, J., Morgan-Followell, B., Pitt, D., Racke, M.K., and Boster, A., 2012. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal of CNS Disease, 4, 81103.

OGorman, C. Lucas, R., Taylor, B., 2012. Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms. Int. J. Mol. Sci., 13, 11718-11752.

Oh, J., OConnor, P.W., 2014. Teriflunomide in the Treatment of Multiple Sclerosis: Current Evidence and Future Prospects. Ther Adv Neurol Disord., 7 (5), 239-252.

Oreja-Guevara, C., Wiendl, H., Kieseier, B.C., Airas, L., 2014. Specific Aspects of Modern Life for People with Multiple Sclerosis: Considerations for the Practitioner. Ther Adv Neurol Disord., 7 (2), 137-149.

Pandit, L., Murthy, J.M.K., 2011. Treatment of Multiple Sclerosis. Ann India Acad Neurol., 14 (Suppl1), S65-S69.

Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., OConnor, P., Sandberg-Wolheim, M., Thompson, A.J., Waubant, E., Weinshenker, B., Wolinsky, J.S., 2011. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Ann Neurol., 69, 292-302.

Ross, A.P., Halper, J., and Harris, C.J., 2012. Assessing Relapses and Response to Relapse Treatment in Patients with Multiple Sclerosis. Int J MS Care, 14, 148-159.

Ross, A.P., Ben-Zacharia, A., Harris, C., Smrtka, J., 2013. Multiple Sclerosis, Relapses, and the Mechanism of Action of Adrenocorticotropic Hormone. Frontiers in Neurol., 4 (21), 1-12.

Steinman, L., 2014. Immunology of Relapse and Remission in Multiple Sclerosis. Annu Rev Immunol., 32, 257-281.

Torkildsen, , Myhr, K-M, B, L., 2015. Disease-Modifying Treatments for Multiple Sclerosis A Review of Approved Medications. European Journal of Neurol., 23 (Suppl.1), 18-27.

Totaro, R., Carmine, C.D., Costantino, G., Fantozzi, R., Bellantonio, P., Fuiani, A., Mundi, C., Ruggieri, S., Marini, C., Carolei, A., 2015. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Multiple Sclerosis Intern., doi: 10.1155/2015/763418.

Weinstock-Guttman, B. 2013. An Update on New and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis. Am J Manag Care, 19 (17), S343-S354.

Williams, U.E., Oparah, S.K., Philip-Ephraim E.E., 2014. Disease Modifying Therapy in Multiple Sclerosis. Intern. Schol. Research Notic., http://dx.doi.org/10.1155/2014/307064

Wu, G.F., Alvarez, E., 2011. The Immuno-pathophysiology of Multiple Sclerosis. Neurol Clin., 29 (2), 257-278.

DOI: https://doi.org/10.24071/jpsc.00606